Alpha-Mannosidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Alpha-mannosidosis is an autosomal
recessive lysosomal storage disease caused by MAN2B1 gene mutations. It is
diagnosed by detecting low levels of acidic alpha-mannosidase enzyme activity
in peripheral blood leukocytes or cultured skin fibroblasts, with affected
individuals displaying 5–15% of regular leukocyte activity. In most patients,
the disease is clinically recognised in the first decade of life, progression
is slow, and ataxia develops between 20 to 30 years. Long-term enzyme
replacement therapy (ERT) is a treatment option for alpha-mannosidosis, and the
first human recombinant form of alpha-mannosidase available for ERT is
velmanase alfa. Patients with alpha-mannosidosis who were treated with
velmanase alfa improved in biomarkers, motor function, pulmonary function,
immunologic profile, and quality of life in clinical trials. Intracellular
accumulation of mannose-rich oligosaccharides causes various clinical symptoms,
including hearing loss, intellectual disabilities, and motor function and
speech impairment.
- The prevalence of Alpha-mannosidosis ranges from 1 to 2 cases
per 500,000 live birth in the USA.
Thelansis’s “Alpha-Mannosidosis Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Alpha-Mannosidosis
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Alpha-Mannosidosis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Alpha-Mannosidosis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment